Posted on Jul 01, 2021

Valcon Medical Granted Authorisation by The Danish Medicines Agency for Manufacturing Cannabis Bulk Extracts under the Pilot Programme

With the authorisation to manufacture cannabis bulk extracts under the pilot programme, the company will leverage its expertise to manufacture high-quality cannabis bulk extracts, ensuring strict adherence to regulations and guidelines.

COPENHAGEN, DENMARK, July 01, 2023 - Valcon Medical, a leading pharmaceutical company specialising in innovative healthcare solutions, is pleased to announce that it has received official authorisation from The Danish Medicines Agency to manufacture cannabis bulk extracts under the pilot programme. This authorisation marks a significant milestone for Valcon Medical and reinforces its commitment to providing safe and effective treatments to chronic patients.


The Danish Medicines Agency, renowned for its stringent evaluation process, has granted Valcon Medical the necessary approval to manufacture cannabis bulk extracts as part of the pilot programme. This authorisation allows Valcon Medical to contribute to researching and developing cannabis-based medicines, ensuring compliance with all relevant regulations and guidelines.


Denmark Launches Pilot Programme for Medicinal Cannabis


In a significant step towards expanding patient access to alternative treatments, Denmark has initiated a pilot programme for medicinal cannabis. The Danish government aims to evaluate the potentia lbenefits and challenges associated with the use of cannabis for medical purposes, paving the way for future regulations and improved patient care. 

The pilot programme, which began in 2018, allows selected patients suffering from various chronic conditions to access medicinal cannabis products prescribed by authorised healthcare professionals. The initiative is part of Denmark's ongoing efforts to explore the therapeutic potential of cannabis and ensure patient safety and quality control.


Under the programme, patients with conditions such as chronic pain, multiple sclerosis, and chemotherapy-induced nausea will have the opportunity to try cannabis-based treatments. The Danish Medicines Agency will closely monitor the patients' progress, collecting data on the effectiveness and safety of the prescribed cannabis products.


To ensure the quality and safety of medicinal cannabis, the Danish government has established strict regulations for cultivation, production, and distribution. Only licensed producers who meet stringent quality standards are permitted to supply cannabis products to patients participating in the pilot programme. This approach aims to guarantee that patients receive reliable and standardised treatments.


Denmark's pilot programme aligns with the growing global recognition of the therapeutic potential of cannabis. Numerous studies have shown promising results intreating various conditions, including chronic pain, epilepsy, and certain mental health disorders. By conducting this pilot programme, Denmark aims to gather valuable data and insights to inform future regulations and ensure the safe and effective use of medicinal cannabis.

The Danish Medicines Agency's authorisation of Valcon Medical's manufacturing activities under the pilot programme highlights the company's commitment to compliance, patient safety, and ethical practices. Valcon Medical will continue collaborating with healthcare professionals, regulatory authorities, and other stakeholders to ensure responsible manufacturing and distribution of cannabis-based medicines.


About Valcon Medical

Valcon Medical is a leading pharmaceutical company dedicated to improving patient outcomes through innovative healthcare solutions. With a focus on research, development, manufacturing, and distribution of pharmaceutical products, Valcon Medical strives to address unmet medical needs and enhance the quality of life for patients worldwide. The company is committed to adhering to the highest quality, safety, and ethical standards.